Taylor Ortiz, MD
Medical Oncology · Methuen, MANPI 1306065446
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Bayer at 34.5% of the total. Reporting peaked in 2019 at $1,224 and has fallen 93.6% since, to $79 in 2025. That places this record below the midpoint for medical oncology clinicians in MA, where the typical reported total is $2,567.
Across 101 payments — averaging $29.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- Johnson & Johnson$290
- Pfizer$168
- Novocure Inc.$147
- Merck$146
- E.r. Squibb & Sons, L.L.C.$137
- plus $1K from 29 others
Across 89 payments — averaging $5712.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$202K
- Eli Lilly$113K
- Janssen Research & Development, LLC$105K
- AstraZeneca$75K
- Pharmacyclics LLC, An Abbvie Company$14K
- Incyte Corporation$63
What the payments were for
- Consulting fees$1,02834%
- Food & beverage$1,69156%
- Education$29310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $1,040 |
| Johnson & Johnson | 12 | $290 |
| Pfizer | 14 | $168 |
| Novocure Inc. | 1 | $147 |
| Merck | 12 | $146 |
| E.r. Squibb & Sons, L.L.C. | 9 | $137 |
| AstraZeneca | 7 | $127 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $125 |
| Foundation Medicine, Inc. | 3 | $92 |
| Genentech USA, Inc. | 2 | $88 |
| Caris MPI, Inc. | 1 | $79 |
| Rigel Pharmaceuticals, Inc. | 1 | $64 |
| Sanofi | 4 | $63 |
| Amgen | 3 | $57 |
| Puma Biotechnology, Inc. | 2 | $42 |
| Verastem, Inc. | 2 | $39 |
| Novartis | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Lilly USA, LLC | 2 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Epizyme, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $16 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Genmab U.S., Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $12 |
| Dova Pharmaceuticals | 1 | $12 |
| Gilead | 1 | $12 |
| Incyte Corporation | 1 | $12 |
| Sirtex Medical Inc | 1 | $12 |
| Exelixis Inc. | 1 | $11 |
| Boehringer Ingelheim | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stivarga$1,028
How this compares
$3,012 in reported general payments places this provider in the 50th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $23,949 |
| Dexamethasone | 19 | $380 |
| Gabapentin | 11 | $137 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $114 |
| Oxycodone Hcl | 13 | $99 |
| Prednisone | 20 | $96 |
| Prochlorperazine Maleate | 12 | $95 |
| Ondansetron OdtOndansetron | 14 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $23,94938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Methuen
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- James O'LearyWaltham$508K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Mary DonnellyGardner$392K
- Jeremy AbramsonBoston$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.